Cortisol Excess May Predict Poor Outcomes in Adrenal Cancer

Higher urinary free cortisol (UFC) levels at diagnosis were associated with an increased risk for tumor recurrence or progression in patients with Cushing syndrome secondary to adrenocortical carcinoma (ACC). Both tumor size and UFC levels independently predicted metastatic disease at diagnosis. Researchers analyzed 101 patients with overt Cushing syndrome due to ACC to assess the link between hypercortisolism severity and survival outcomes. Patients were categorized based on UFC levels relative to the upper limit of normal: mild (< 2x ULN), moderate (2-5x ULN), and severe (> 5x ULN). Overall survival was median 19.4 months, while disease-free survival varied significantly by stage; for patients with localized disease achieving complete resection, median DFS was 12.3 months, and for those with metastatic disease, PFS was 5.6 months. A combined analysis suggested that the risk for tumor recurrence or progression increased with hypercortisolism severity, finding a 21% increase in the mild group, a 52% increase in the moderate group, and a 57% increase in the severe group (P = .035). Multivariate analysis identified older age, elevated UFC, hypokalemia, and a higher Ki-67 index as independent risk factors.

The study moves beyond simply establishing correlation to suggest that hormonal status acts as an independent prognostic factor in a context where standard clinicopathological markers are considered. The finding that hypercortisolism severity independently predicts recurrence/progression suggests a deeper biological mechanism linking chronic cortisol excess and tumor aggressiveness, rather than just a correlation with poor outcomes. The significant stratification based on UFC levels—mild, moderate, severe—provides a tangible risk gradient that clinical practice can utilize, even if the retrospective design introduces selection bias. The specific pattern of increased risk across severity groups (21% to 57%) suggests that the relationship between hypercortisolism and prognosis is not linear but rather escalates with the degree of HPA axis dysregulation present at diagnosis. Further inquiry must focus on whether UFC levels reflect differential rates of tumor progression, or if they are simply a consequence of advanced, treatment-refractory disease that dictates a worse prognosis regardless of tumor biology. What are the biological pathways mediating this link between cortisol excess and metastatic behavior in ACC? Does focusing on the composite endpoint (recurrence/progression) provide a more robust signal than individual survival metrics alone?